A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V
about
Prediction of abacavir resistance from genotypic data: impact of zidovudine and lamivudine resistance in vitro and in vivoHIV-1 RT Inhibitors with a Novel Mechanism of Action: NNRTIs that Compete with the Nucleotide SubstrateHIV-1 subtype B protease and reverse transcriptase amino acid covariationGenotypic testing for human immunodeficiency virus type 1 drug resistance.Antiretroviral resistance during successful therapy of HIV type 1 infection.Rapid and simple phenotypic assay for drug susceptibility of human immunodeficiency virus type 1 using CCR5-expressing HeLa/CD4(+) cell clone 1-10 (MAGIC-5)Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): multicenter study of patients treated with RT inhibitorsDiversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype.Phenotypic and genotypic analysis of biologically cloned human immunodeficiency virus type 1 isolates from patients treated with zidovudine and lamivudine.Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase.Frequency of mutations conferring resistance to nucleoside reverse transcriptase inhibitors in human immunodeficiency virus type 1-infected patients in Korea.Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine.Optimizing ART adherence: update for HIV treatment and preventionDetection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants.Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase.Quality control trial for human immunodeficiency virus type 1 drug resistance testing using clinical samples reveals problems with detecting minority species and interpretation of test results.A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.Emtricitabine: a once-daily nucleoside reverse transcriptase inhibitor.The impact of the M184V substitution on drug resistance and viral fitness.Fixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection.HIV-1 drug resistance mutations: an updated framework for the second decade of HAARTColinearity of reverse transcriptase inhibitor resistance mutations detected by population-based sequencingThe Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.Effectiveness and metabolic complications after 96 weeks of a generic fixed-dose combination of stavudine, lamivudine, and nevirapine among antiretroviral-naive advanced HIV-infected patients in Thailand: A prospective study.Prevalence and conditions of selection of E44D/A and V118I human immunodeficiency virus type 1 reverse transcriptase mutations in clinical practiceRate of virological treatment failure and frequencies of drug resistance genotypes among human immunodeficiency virus-positive subjects on antiretroviral therapy in Spain.Correlation of phenotypic zidovudine resistance with mutational patterns in the reverse transcriptase of human immunodeficiency virus type 1: interpretation of established mutations and characterization of new polymorphisms at codons 208, 211, and 2Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase.Identification of a novel resistance (E40F) and compensatory (K43E) substitution in HIV-1 reverse transcriptase.Differential maintenance of the M184V substitution in the reverse transcriptase of human immunodeficiency virus type 1 by various nucleoside antiretroviral agents in tissue culture.HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.Mutations and polymorphisms associated with antiretroviral drugs in HIV-1C-infected African patients.Comparative analysis of drug resistance mutations in the human immunodeficiency virus reverse transcriptase gene in patients who are non-responsive, responsive and naive to antiretroviral therapy.Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibilityLamivudine resistance in human T-cell leukemia virus type 1 may be due to a polymorphism at codon 118 (V-->I) of the reverse transcriptase.Baseline antiretroviral drug susceptibility influences treatment response in patients receiving saquinavir-enhancing therapy.Prevalence of the mutational pattern E44D/A and/or V118I in the reverse transcriptase (RT) gene of HIV-1 in relation to treatment with nucleoside analogue RT inhibitors.The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response.Sustained high proportion of zidovudine-resistant HIV variants despite prolonged substitution of zidovudine by other nucleoside reverse transcriptase inhibitors.
P2860
Q24535740-7E559C51-29F1-4A6A-B132-93A404320175Q28250395-C066AF92-292C-4799-8573-1983079C5875Q28469203-22539574-C986-4F62-97B4-1D3FAEAA856EQ33906239-C423DB94-4BF3-4AB5-B098-9F636A9FEAD2Q33919308-CC3206E6-911E-40E7-B97E-38E599B64D18Q33981401-A23A561C-83BD-4160-BB3A-9FB6ED0D6D02Q33982354-A930A87D-9FC1-4CE9-9794-8035E9D72964Q34032267-CFF2E605-98DA-4842-87AC-E6EA598D2195Q34251987-079D4329-EC6A-4CCB-9179-223220055577Q34339657-75FD445F-4DA2-4E14-8720-C9C87E2848ECQ34454702-902DDC3B-C7B9-4896-8BA2-B6C739034D9BQ34465037-B07FF928-DADD-43CE-AB13-67D449C24AD1Q34717901-B7EF28DB-30A8-4EC6-B238-864ADF0C942DQ35140450-26D7B651-31F3-454E-872C-8B495BC0F7B8Q35566910-30617C64-DE95-4CBC-BFB7-FFCE49D27670Q35638409-85CA7B0D-2AEA-4282-BBCC-061A957E43DEQ35742512-71F08598-94ED-4560-9CAC-9CA44A0A5816Q35762280-FD4EEA6A-8C0B-4033-A076-624CE376B8F4Q35917349-BD9940BC-B65E-4F7D-B752-50BF5B8C3159Q36322100-11E36DA4-6CAC-4FE4-991E-4FA4E2B57168Q36900010-3C4D32A1-D962-46BB-8F1E-BB47898EEC6CQ36950126-3D883F02-3848-482F-B8C7-1A99C5ACCBAAQ37018369-C8841FBB-5254-42A8-BC68-CA01AF02ED32Q37672806-594E6726-34C9-4793-8EF4-DC080B68EFB8Q39476701-D5D1FD7C-E7DA-4252-8322-F65668D81716Q39664996-9262A054-C978-4BAD-A584-5A034E45AAC0Q39730755-005D794D-F7A7-42EB-B763-0D6BC61127D6Q39912641-8E0AEEC7-C5C2-409D-B28F-412782F4BC68Q40013658-C2A5D64F-2F7D-4C9A-A9F8-D5348E76241DQ40291316-BBFCD53C-362C-4FF1-B243-B244FF3FC27DQ40642031-953973A7-22CD-42A8-9A79-EE7507397968Q40785692-40C76FCC-671F-4FD8-B680-94A61E68BAF4Q40800372-5E771E5F-D098-4853-93FD-AECB6F03AD5AQ40821165-A901DFE9-C51C-4734-91F1-94BBDACE4088Q42151695-9B37C48E-2886-4463-8789-2E8CA17A50C1Q42700019-28298BFE-4097-4E01-81F3-30F8A4BE128CQ43822039-9C9D1012-A4C8-49A1-87EF-2101453F0E8DQ43856149-7E9B273E-D18C-4E22-92CE-4B0A887917E1Q43993272-EB61C205-3E8C-482D-AB09-F04081498479Q44124733-280B2835-7A7C-434D-A84B-6C96E02EEF38
P2860
A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
A novel human immunodeficiency ...... n the absence of mutation 184V
@en
A novel human immunodeficiency ...... the absence of mutation 184V.
@nl
type
label
A novel human immunodeficiency ...... n the absence of mutation 184V
@en
A novel human immunodeficiency ...... the absence of mutation 184V.
@nl
prefLabel
A novel human immunodeficiency ...... n the absence of mutation 184V
@en
A novel human immunodeficiency ...... the absence of mutation 184V.
@nl
P2093
P2860
P1476
A novel human immunodeficiency ...... n the absence of mutation 184V
@en
P2093
A van Cauwenberge
B A Larder
C van Den Eynde
M van Houtte
P Dehertogh
V De Vroey
P2860
P304
P356
10.1128/AAC.44.3.568-573.2000
P407
P577
2000-03-01T00:00:00Z